Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Compugen (NASDAQ:CGEN) announced its upcoming presentation at ESMO 2025 in Berlin, Germany.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen (NASDAQ:CGEN) announced its upcoming presentation at ESMO 2025 in Berlin, Germany. The presentation will feature a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum resistant ovarian cancer patients.
The analysis includes data from trials testing COM701 as both monotherapy and combination therapy in heavily pretreated patients. Dr. Oladapo Yeku from Massachusetts General Hospital will present the findings on October 18, 2025 at 12:00-12:45 CEST. The poster presentation (#1196P) will subsequently be available on Compugen's website.
Details
News Market Reaction – CGEN
The recorded move for CGEN in the trading session of this news was -1.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
Poster details:
Title: COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials
Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital,
Poster presentation number: 1196P
Date of poster presentation: Saturday, October 18; 12:00-12:45 CEST
The poster will be available in the publications section of Compugen's website, www.cgen.com
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to activate the immune system against cancer. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-a-pooled-analysis-of-com701-phase-1-trials-in-platinum-resistant-ovarian-cancer-at-esmo-2025-302514758.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.